Biomarin Pharmaceutical (BMRN) Change in Accured Expenses (2009 - 2026)

Biomarin Pharmaceutical has disclosed Change in Accured Expenses across 18 years of filings, most recently posting $3.1 million for Q1 2026.

• Quarterly Change in Accured Expenses rose 49.83% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.2 million (up 300.62% YoY) and the FY2025 annual result came in at $66.1 million, up 305.14% from the prior year.
• Change in Accured Expenses eased to $3.1 million in Q1 2026, from $44.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $76.6 million in Q2 2022 and troughed at -$78.1 million in Q1 2022.
• A 5-year average of $7.0 million and a median of $3.3 million in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 2452.39% — and 2024, when it plunged 559.03%.
• Tracing BMRN's Change in Accured Expenses over 5 years: stood at $62.3 million in 2022, then tumbled by 85.14% to $9.3 million in 2023, then tumbled by 559.03% to -$42.5 million in 2024, then surged by 204.18% to $44.2 million in 2025, then plunged by 92.99% to $3.1 million in 2026.
• Business Quant data shows BMRN's Change in Accured Expenses at $3.1 million in Q1 2026, $44.2 million in Q4 2025, and $18.8 million in Q3 2025.